Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name file name title title
tabling member	label

Search

1385194

	registered interest
	date	06/12/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Immunotherapy: Shortages
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what communications have been issued by the NHS in England about the immunoglobulin shortage to patient groups supporting people with immunodeficiency; and whether the NHS in England has communicated directly with patients to explain the situation and how it will affect them.
	tabling member printed	Lord Mendelsohn
	uin	HL4726
	answer	answer is ministerial correction date of answer 20/12/2021 answer text <p>With the input of clinicians, professional bodies and patient groups, NHS England and NHS Improvement and the UK Primary Immunodeficiency Network have developed a patient information leaflet which was issued to National Health Service trusts on 8 November 2021, with a request to discuss and share with patients as part of individual clinical conversations. NHS England and NHS Improvement have also shared the leaflet with patient groups to circulate to affected members.</p><p>The patient information leaflet highlights that, due to the COVID-19 pandemic, fewer people have been able to donate blood, which has impacted the availability of immunoglobulin products both globally and in the United Kingdom. The patient information leaflet also explains what the impact of the global shortage of immunoglobulin products may mean for UK patients and how they can access support. A copy of the patient leaflet, <em>Immunoglobulin replacement therapy: Information for patients from the NHS and the UK Primary Immunodeficiency Network</em> is attached.</p> answering member printed Lord Kamall question first answered 20/12/2021 13:19:29 answering member 4909 label Biography information for Lord Kamall attachment 1 file name B0910_ii_Immunoglobulin - patient information leaflet_041121.docx title Immunoglobulin replacement therapy: Information fo
	tabling member	4286 label Biography information for Lord Mendelsohn

1437285

	registered interest
	date	01/03/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Disease Control
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans, if any, they have to work with charities that represent clinically extremely vulnerable people to ensure that these groups rapidly receive communications concerning their risk from COVID-19 as restrictions and mandatory isolation comes to an end on 1 April.
	tabling member printed	Lord Mendelsohn
	uin	HL6546
	answer	answer is ministerial correction date of answer 15/03/2022 answer text <p>We will continue to meet with charities and stakeholders representing those whose immune system means they are at higher risk of serious illness from COVID-19. The Chief Executive of the UK Health Security Agency, Dr Jenny Harries, is the clinical lead for the programmes supporting these patients and has met with charities at stakeholder engagement sessions.</p> answering member printed Lord Kamall question first answered 15/03/2022 12:07:32 answering member 4909 label Biography information for Lord Kamall
	tabling member	4286 label Biography information for Lord Mendelsohn

1462730

	registered interest
	date	12/05/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Evusheld
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government why they have not recognised the laboratory assay tests conducted in (1) the US, and (2) the EU, on Evusheld against Omicron subvariants.
	tabling member printed	Lord Mendelsohn
	uin	HL215
	answer	answer is ministerial correction date of answer 25/05/2022 answer text <p>We understand that the United States of America has increased the suggested dose of Evusheld, in line with in vitro results showing that Evusheld has reduced efficacy against some Omicron subvariants. The Food and Drug Administration’s in vitro data was pseudovirus data, whereas the tests being conducted by the UK Health Security Agency (UKHSA) are based on live virus data. The European Medicines Agency has acknowledged the possibility that Evusheld has reduced efficacy against Omicron subvariants, based on laboratory studies. The data generated by the UKHSA will enhance our understanding of the effectiveness of Evusheld's neutralisation of Omicron subvariants, including BA.2.</p> answering member printed Lord Kamall question first answered 25/05/2022 11:30:45 answering member 4909 label Biography information for Lord Kamall
	tabling member	4286 label Biography information for Lord Mendelsohn

1464287

	registered interest
	date	18/05/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Disease Control
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the Written Answer by Lord Kamall on 27 April (HL7561), what conclusions they have reached following meetings with groups representing the immunocompromised community on how they can be involved in (1) creating, and (2) disseminating, (a) communication, and (b) guidance, to people about how to safely manage their ongoing risk.
	tabling member printed	Lord Mendelsohn
	uin	HL347
	answer	answer is ministerial correction date of answer 06/06/2022 answer text <p>We regularly engage with charities and patient organisation representing and supporting immunocompromised and immunosuppressed people. Further to discussions with these groups, we are establishing an engagement forum for charities and patient organisations to discuss issues relating to the enhanced protection programme and to seek the views of these stakeholders in advance of any updates to guidance. We will continue to update these stakeholders on the enhanced protection programme through webinars, meetings and correspondence.</p><p> </p><p>The enhanced protection programme is a tripartite scheme administered by the Department, NHS England and NHS Improvement and the UK Health Security Agency (UKHSA). Dame Jenny Harries, the Chief Executive of the UKHSA, is the senior responsible owner for the</p><p>programme. There is no formal process for designating patient organisations as stakeholders for the programme.</p> answering member printed Lord Kamall grouped question UIN HL348 HL349 question first answered 06/06/2022 10:59:57 answering member 4909 label Biography information for Lord Kamall
	tabling member	4286 label Biography information for Lord Mendelsohn

1464288

	registered interest
	date	18/05/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Disease Control
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have to (1) communicate, and (2) consult, with (a) charities, and (b) patient organisations, as part of the COVID-19 enhanced protection programme (EPP); and what format this will take.
	tabling member printed	Lord Mendelsohn
	uin	HL348
	answer	answer is ministerial correction date of answer 06/06/2022 answer text <p>We regularly engage with charities and patient organisation representing and supporting immunocompromised and immunosuppressed people. Further to discussions with these groups, we are establishing an engagement forum for charities and patient organisations to discuss issues relating to the enhanced protection programme and to seek the views of these stakeholders in advance of any updates to guidance. We will continue to update these stakeholders on the enhanced protection programme through webinars, meetings and correspondence.</p><p> </p><p>The enhanced protection programme is a tripartite scheme administered by the Department, NHS England and NHS Improvement and the UK Health Security Agency (UKHSA). Dame Jenny Harries, the Chief Executive of the UKHSA, is the senior responsible owner for the</p><p>programme. There is no formal process for designating patient organisations as stakeholders for the programme.</p> answering member printed Lord Kamall grouped question UIN HL347 HL349 question first answered 06/06/2022 10:59:57 answering member 4909 label Biography information for Lord Kamall
	tabling member	4286 label Biography information for Lord Mendelsohn

1464289

	registered interest
	date	18/05/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Disease Control
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government who is responsible for leading the COVID-19 enhanced protection programme (EPP); and what is the process for (1) charities, and (2) patient organisations, to be designated as stakeholders for the programme.
	tabling member printed	Lord Mendelsohn
	uin	HL349
	answer	answer is ministerial correction date of answer 06/06/2022 answer text <p>We regularly engage with charities and patient organisation representing and supporting immunocompromised and immunosuppressed people. Further to discussions with these groups, we are establishing an engagement forum for charities and patient organisations to discuss issues relating to the enhanced protection programme and to seek the views of these stakeholders in advance of any updates to guidance. We will continue to update these stakeholders on the enhanced protection programme through webinars, meetings and correspondence.</p><p> </p><p>The enhanced protection programme is a tripartite scheme administered by the Department, NHS England and NHS Improvement and the UK Health Security Agency (UKHSA). Dame Jenny Harries, the Chief Executive of the UKHSA, is the senior responsible owner for the</p><p>programme. There is no formal process for designating patient organisations as stakeholders for the programme.</p> answering member printed Lord Kamall grouped question UIN HL347 HL348 question first answered 06/06/2022 10:59:57 answering member 4909 label Biography information for Lord Kamall
	tabling member	4286 label Biography information for Lord Mendelsohn

1441625

	registered interest
	date	15/03/2022
	answering body	Department for Levelling Up, Housing and Communities
	answering dept id	211
	answering dept short name	Levelling Up, Housing and Communities
	answering dept sort name	Levelling Up, Housing and Communities
	hansard heading	Landlord and Tenant Act 1954
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government when they intend to undertake the review of the Landlord and Tenant Act 1954, announced in December 2021; and why that review has been delayed.
	tabling member printed	Lord Mendelsohn
	uin	HL6979
	answer	answer is ministerial correction date of answer 29/03/2022 answer text <p>We know there is concern that the Landlord and Tenant Act 1954, part II, has not kept pace with today’s commercial property sector. <br> <br> Government announced <a href="https://www.gov.uk/government/news/business-evictions-ban-extended-until-march" target="_blank">a review of the landlord and tenant legislation</a>  in December 2020. The review will develop proposals for a framework that helps support the efficient, flexible use of space and supports high streets and town centres. <br> <br> Over the last year, Government has prioritised developing an <a href="https://www.gov.uk/government/news/new-laws-and-code-to-resolve-remaining-covid-19-commercial-rent-debts" target="_blank">exit strategy from the moratorium on commercial evictions</a> , and resolution of pandemic-related rent debt via the Commercial Rent (Coronavirus) Act, which received Royal Assent on 24 March. Government recommitted to the review as part of the <a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1005041/Build_Back_Better_High_Streets.pdf" target="_blank">Build Back Better High Streets</a> strategy in July 2021, and officials are currently engaging across the sector to inform the scope and focus of the review; further details will be announced in due course.</p> answering member printed Lord Greenhalgh attachment 1 file name HL6979 Exit strategy from the moratorium on commercial evictions.docx title Exit strategy from the moratorium on commercial ev 2 file name HL 6979 Build Back Better High Streets.pdf title Build Back Better High Streets 3 file name HL 6979 Review of the landlord and tenant legislation.docx title Review of the landlord and tenant legislation question first answered 29/03/2022 16:57:24 answering member 4877 label Biography information for Lord Greenhalgh
	tabling member	4286 label Biography information for Lord Mendelsohn

1456676

	registered interest
	date	31/03/2022
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	Small Business Commissioner
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what conclusions they reached with the Small Business Commissioner regarding the implications of the results of the Increasing the scope and powers of the Small Business Commissioner consultation, which ran from 1 October 2020 to 24 December 2020; what proposals they intend to come up with as a result of this; and when such proposals will be implemented.
	tabling member printed	Lord Mendelsohn
	uin	HL7566
	answer	answer is ministerial correction date of answer 19/04/2022 answer text <p>We are committed to strengthen the powers of the Small Business Commissioner to support small businesses.</p><p> </p><p>We are working through the impact of any new powers with the Commissioner to better understand resourcing implications of each option and also working through the impact on businesses.</p> answering member printed Lord Callanan question first answered 19/04/2022 15:02:37 answering member 4336 label Biography information for Lord Callanan
	tabling member	4286 label Biography information for Lord Mendelsohn

1456675

	registered interest
	date	31/03/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what steps they are taking to improve communication with immunocompromised patients who have not been informed about access to free COVID-19 PCR tests; and what steps they will take to ensure that those patients continue to get the latest information about treatments for COVID-19.
	tabling member printed	Lord Mendelsohn
	uin	HL7565
	answer	answer is ministerial correction date of answer 25/04/2022 answer text <p>Vulnerable patients who are clinically eligible for antiviral and antibody treatments have been identified digitally, where possible. These patients should have received a ‘pre-notification’ letter or email to advise them that they may be eligible to receive these treatments directly, should they test positive for COVID-19. Some potentially eligible patients are not centrally identifiable using national databases, such as those who are newly diagnosed and some cancer patients. Those patients are being contacted directly by their consultants.</p><p> </p><p>NHS England circulated information to general practices and wrote to medical directors at National Health Service trusts and clinical commissioning groups, to provide an update on patient access to treatments from COVID Medicine Delivery Units (CMDU) from 1 April 2022. This information has been cascaded to clinicians to advise their patients on accessing treatments from CMDUs. Consultants and specialists have been requested to contact eligible patients to provide further information.</p> answering member printed Lord Kamall question first answered 25/04/2022 16:41:46 answering member 4909 label Biography information for Lord Kamall
	tabling member	4286 label Biography information for Lord Mendelsohn

1433435

	registered interest
	date	21/02/2022
	answering body	Home Office
	answering dept id	1
	answering dept short name	Home Office
	answering dept sort name	Home Office
	hansard heading	Immigration Controls: USA
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what verification checks are conducted on the permitted US Homeland Security procedures at UK airports; who conducts these checks; in which department the people that conduct these checks are based; and when was the last time these checks were conducted.
	tabling member printed	Lord Mendelsohn
	uin	HL6289
	answer	answer is ministerial correction date of answer 07/03/2022 answer text <p>Under the US Immigration Advisory Program, US Customs and Border Protection (CBP) officers have operated in an advisory capacity at Heathrow airport, since 2007, to support airlines in identifying passengers who may be inadmissible to the US and should not board flights to the US. This reflects an established recommended practice of Annex 9 to the Convention on International Civil Aviation (the Chicago Convention).</p><p>The CBP officers hold no authority in the UK, conduct no formal checks and can only advise airline staff. The decision whether or not to board a passenger rests with the airline.</p><p>We do not publish the specific details of the arrangement with the Department of Homeland Security for operational reasons.</p> answering member printed Baroness Williams of Trafford grouped question UIN HL6290 question first answered 07/03/2022 16:19:26 answering member 4311 label Biography information for Baroness Williams of Trafford
	tabling member	4286 label Biography information for Lord Mendelsohn